Business Strategy

There are more than 6,000 recognized orphan diseases in the United States and nearly 300 FDA approved treatments. Some examples of widely known orphan diseases are thalassemia, sickle cell anemia, cystic fibrosis, and Huntington’s disease; additionally many forms of cancer are designated as orphan diseases. These diseases represent an unmet medical need and present an opportunity to companies such as EGT.

EGT’s business strategy employs gene replacement through gene therapy and gene expression correction through chromatin modification as the basis for treatments for orphan diseases. The company seeks to develop such treatments first in the United States and then to make them available in selected countries worldwide.

The key element of the EGT strategy is the accelerated development of its lead products. In addition, the company will build value through the emergence of additional products from its patent portfolio. Finally, EGT will maintain an ongoing effort to identify new opportunities through collaboration with leading universities.

Two of the Company’s technologies designated as its lead products (Thalagen™ for thalassemia and CG-1521 for refractory prostate cancer) have been developed to the extent that these are near entry into human clinical trials. Most start-up companies begin operations based primarily on a theoretical concept. In contrast, EGT begins with well-tested technologies and the key element, a demonstrated “Proof of Concept”. This allows EGT to begin clinical trials, while other companies are not in a position to begin clinical trials until 3 – 6 years after startup.